GOLD Guidelines on Biologics in COPD
The latest GOLD 2026 guidelines now recommend biologic therapies—specifically dupilumab and mepolizumab—as add-on treatment for patients with COPD who have blood eosinophil counts ≥300 cells/µL and continue to experience ≥2 moderate or ≥1 severe exacerbations per year despite optimized triple inhaled therapy (LAMA/LABA/ICS). 1
Which Biologics Are Recommended
The GOLD 2026 report introduces two specific biologics for eosinophilic COPD:
Dupilumab (300 mg subcutaneously every 2 weeks)
- Blocks the shared receptor for IL-4 and IL-13, key drivers of type 2 inflammation
- Demonstrated 30-34% reduction in moderate/severe exacerbations versus placebo 2, 3
- Provides additional benefits beyond exacerbation reduction:
- Improved lung function (FEV1 increase of 82-83 mL at week 12, sustained through week 52)
- Better quality of life (SGRQ improvement of -3.4 points at week 52)
- Reduced respiratory symptoms (E-RS-COPD improvement of -1.1 points)
- Particularly effective in patients with elevated FeNO ≥20 ppb 4
Mepolizumab (100 mg subcutaneously every 4 weeks)
- Targets interleukin-5, central to eosinophilic inflammation
- Demonstrated 21% reduction in moderate/severe exacerbations versus placebo 5
- Did NOT show significant improvements in quality of life or symptoms beyond exacerbation reduction
- Requires approximately 4.8 years to prevent one exacerbation, compared to 2.3-3.1 years for dupilumab 4
Patient Selection Criteria
Biologics should be considered when ALL of the following are met:
- Blood eosinophil count ≥300 cells/µL (consistent threshold across all trials)
- Exacerbation history: ≥2 moderate OR ≥1 severe exacerbation in the previous year
- Already on optimized triple inhaled therapy (LAMA/LABA/ICS)
- Continued exacerbations despite triple therapy
Important Nuance on the "E" Classification
The GOLD 2026 classification now includes patients with just one moderate exacerbation in Group E 6. However, biologics should NOT be initiated after a single moderate exacerbation—the evidence base and recommendations specifically require ≥2 moderate or ≥1 severe exacerbations 1. A single moderate exacerbation has limited clinical impact at the population level and carries a future exacerbation risk typically below 50% 6.
Choosing Between Dupilumab and Mepolizumab
Dupilumab appears to be the preferred biologic based on the totality of evidence:
- Broader efficacy profile: Reduces exacerbations AND improves lung function, quality of life, and symptoms 2, 3
- More efficient exacerbation prevention: Number needed to treat is lower (2.3-3.1 vs 4.8 years to prevent one exacerbation) 4
- Enhanced effect with biomarker stratification: Particularly effective when FeNO ≥20 ppb 4
Mepolizumab may be considered when:
- Dupilumab is contraindicated, not tolerated, or not available
- Cost considerations favor mepolizumab
- Patient preference for less frequent dosing (every 4 weeks vs every 2 weeks)
Stepwise Approach Before Biologics
Before considering biologics, ensure the following escalation pathway has been completed:
Optimize dual bronchodilation (LAMA/LABA) as the foundation
Add ICS to triple therapy if blood eosinophils ≥300 cells/µL and exacerbations persist 7
Consider additional therapies for persistent exacerbations on triple therapy:
Only after exhausting these options should biologics be added 1
Critical Caveats and Pitfalls
Do NOT step down ICS in high-risk exacerbators
- Withdrawing ICS increases exacerbation risk, especially harmful when eosinophils ≥300 cells/µL 7
- Biologics are ADD-ON therapy, not replacements for triple therapy
Blood eosinophil variability
- Eosinophil counts fluctuate; confirm elevation on multiple occasions when possible
- The 300 cells/µL threshold is evidence-based from clinical trials but represents a continuum of risk 1
Limited real-world evidence
- Biologic trials excluded many real-world COPD patients with significant comorbidities
- Cost-effectiveness remains uncertain 1
- Long-term safety data beyond 52-104 weeks are limited
Pneumonia risk with ICS
- Triple therapy increases pneumonia risk (NNH = 33 patients for 1 year) 7
- However, NNT = 4 patients for 1 year to prevent one exacerbation, favoring benefit over harm 7
- Biologics do not eliminate the need for ICS in this population
Not for acute exacerbations
- Biologics are maintenance therapy for exacerbation prevention
- They have no role in treating acute exacerbations
Administration and Monitoring
Dupilumab: 300 mg subcutaneous injection every 2 weeks (can be self-administered after training)
Mepolizumab: 100 mg subcutaneous injection every 4 weeks (can be self-administered after training)
Monitoring should include:
- Exacerbation frequency and severity
- Lung function (FEV1) at 12 weeks and periodically thereafter
- Quality of life assessments (SGRQ or CAT)
- Symptom burden
- Adverse events (injection site reactions, eosinophilia-related complications)
- Consider FeNO measurement if available to identify dupilumab super-responders
Reassess efficacy at 12-24 weeks: If no reduction in exacerbations or improvement in other outcomes, consider discontinuation and alternative strategies.